Clinical Trials on Lymphoblastic Leukemia, Acute in Germany

Total 1240 results

Gruppo Italiano Malattie EMatologiche dell'Adulto
Study Alliance Leukemia (SAL) Group

Completed

Phase III Trial in Acute Promyelocytic Leukemia Patients (APL0406)

Leukemia

Germany, Italy, Austria
Cornerstone Pharmaceuticals

Terminated

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

Relapsed/Refractory Acute Myeloid Leukemia

United States, Spain, Korea, Republic of, France, Australia, Belgium, Austria, Germany, Poland
Clavis Pharma

Completed

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)

Acute Myeloid Leukemia (AML)

United States, Spain, France, Ireland, United Kingdom, Australia, Belgium, Canada, Germany, Italy, Norway, Poland, Romania
Telios Pharma, Inc.
Kartos Therapeutics, Inc.

Active, not recruiting

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Korea, Republic of, Spain, France, Austria, Australia, Germany, Italy
University of Ulm
Jazz Pharmaceuticals

Recruiting

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Acute Myeloid Leukemia

Austria, Germany
University of Ulm

Completed

Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

Acute Myeloid Leukemia

Germany, Austria
Karyopharm Therapeutics Inc

Completed

Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)

Acute Myeloid Leukemia (AML)

Canada, United States, Israel, Netherlands, Denmark, Spain, France, Italy, United Kingdom, Germany, Poland
Kronos Bio

Terminated

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Nucleophosmin 1-mutated Acute Myeloid Leukemia

Israel, Spain, France, United States, Czechia, Hungary, Korea, Republic of, Germany, Italy, Poland, Brazil, Canada
AbbVie
Genentech, Inc.

Terminated

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia | Myelogenous Leukemia | Treatment Naive AML

United States, Australia, France, Germany
Hoffmann-La Roche

Terminated

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (MIRROS)

Leukemia, Myeloid, Acute

Italy, Korea, Republic of, Belgium, Australia, United States, Canada, United Kingdom, Spain, Netherlands, France, Germany, New Zealand, Israel, Norway, Russian Federation, Switzerland, Austria, Finland, Panama
GWT-TUD GmbH

Terminated

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (SAMBA)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

France, Germany
European Society for Blood and Marrow Transplantation
European Organisation for Research and Treatment of Cancer - EORTC; Swiss Group... and other collaborators

Terminated

HCT Versus CT in Elderly AML

Acute Myeloid Leukemia

Switzerland, Netherlands, Germany, France, Australia, Austria, Belgium
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Leukemia

France, Netherlands, Belgium, Czech Republic, Italy, Austria, Germany, Croatia, Turkey
University of Ulm

Terminated

Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)

Acute Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Recruiting

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

FLT3-mutated Acute Myeloid Leukemia

Korea, Republic of, Germany, Italy, Turkey, Czechia, Jordan, Slovenia, Austria, Poland, Japan, Russian Federation, United States, Greece
European Organisation for Research and Treatment...
Janssen Pharmaceuticals; Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

"InDACtion" vs "3+7" Induction in AML

Acute Myeloid Leukemia (AML)

Germany, Belgium, Netherlands, Italy, France, Croatia, Bulgaria, Lithuania, Portugal
Novartis Pharmaceuticals

Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | Large B-cell Lymphoma

Japan, Australia, Germany, Italy, Spain, France, Austria, United States
European Society for Blood and Marrow Transplantation
Hoffmann-La Roche; Amgen

Completed

Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation

Acute Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia

Germany
Arog Pharmaceuticals, Inc.

Recruiting

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States, Germany, Spain, Italy, France, Canada
Heinrich-Heine University, Duesseldorf

Completed

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Hoffmann-La Roche

Completed

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Acute Myeloid Leukemia

Australia, Italy, Canada, United Kingdom, United States, Denmark, Spain, Taiwan, Germany, France
Wuerzburg University Hospital

Completed

Prophylactic Application of Donor-derived TCM After Allogeneic HSCT (PACT)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Germany
Heinrich-Heine University, Duesseldorf
Celgene Corporation

Completed

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT (AZALENA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Germany
Technische Universität Dresden
Celgene Corporation

Terminated

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (LENAMAINT)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

Germany
Hoffmann-La Roche

Terminated

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes, Myelogenous Leukemia, Acute

United States, Canada, Germany
Celgene

Active, not recruiting

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, France, Italy, Korea, Republic of, Spain, United Kingdom, Australia, Canada, Germany, Netherlands, Portugal, Switzerland, Belgium, Sweden
Technische Universität Dresden

Completed

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

Myelodysplastic Syndrome | Acute Myelocytic Leukemia

Germany
University of Ulm
Sunesis Pharmaceuticals

Completed

Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)

Germany
AbbVie

Active, not recruiting

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia (AML)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Puerto Rico, Russian Federation, South Africa, Spain, T... and more
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States, Germany, Denmark
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Leukemia, Myeloid, Acute

United States, Spain, Korea, Republic of, Taiwan, Australia, Canada, Denmark, Hungary, Japan, Finland, Italy, Serbia, Czechia, France, Germany, Sweden, Netherlands, Poland, Russian Federation, Austria, United Kingdom, Romania, Belgium, Bulgar...
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Leukemia, Acute Myeloid (AML)

Japan, United States, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Poland, Spain, Taiwan, Turkey, United Kingdom
AbbVie
Roche-Genentech

Active, not recruiting

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

Acute Myeloid Leukemia (AML)

United States, Australia, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Leukemia, Myeloid, Acute

United States, Germany, Italy, France, Australia, Spain, United Kingdom
Daiichi Sankyo, Inc.

Completed

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

AML

United States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
AstraZeneca

Completed

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients (SPARK-AML1)

Acute Myeloid Leukemia

United States, Italy, United Kingdom, Romania, Japan, Australia, Germany, Spain, France
Genzyme, a Sanofi Company

Completed

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

Acute Myelogenous Leukemia

United States, France, Germany, Canada, Italy
AbbVie
Genentech, Inc.

Active, not recruiting

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (Viale-a)

Acute Myeloid Leukemia (AML)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Norway, Poland, Portugal, Puerto Rico, Russian Federation, South... and more
Janssen Research & Development, LLC

Completed

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Spain, Germany
BerGenBio ASA

Active, not recruiting

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States, Germany, Italy, Norway
Daiichi Sankyo, Inc.

Completed

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) (ACE)

Acute Myeloid Leukemia

United States, Spain, Netherlands, Canada, France, Germany, United Kingdom, Italy, Poland
ImmunoGen, Inc.
Jazz Pharmaceuticals

Active, not recruiting

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Germany, France, Spain, Italy, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
AbbVie

Active, not recruiting

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

Cancer | Acute Myeloid Leukemia (AML)

United States, Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Switzerland, Taiwan, United Kingdom
Technische Universität Dresden
Novartis

Terminated

A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients (DELTA)

Acute Myeloid Leukemia

Germany
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
AGC Biologics S.p.A.

Terminated

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia (TK008)

Acute Leukemia (Category)

Israel, United States, Germany, France, Spain, Belgium, Italy, Greece, Lithuania, Portugal
University of Ulm

Completed

Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

Leukemia, Myeloid, Acute

Germany, Austria

Clinical Trials on Lymphoblastic Leukemia, Acute in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations